non-myeloablative
Showing 26 - 50 of >10,000
Acute Leukemia, Hematologic and Lymphocytic Disorder, Myelodysplastic Syndrome Trial in Duarte (Fludarabine, Itacitinib Adipate,
Active, not recruiting
- Acute Leukemia
- +4 more
- Fludarabine
- +6 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 4, 2023
Single Umbilical Cord Blood Transplantation, Non-myeloablative Conditioning, Acute Lymphocytic Leukemia Trial in Minneapolis
Completed
- Single Umbilical Cord Blood Transplantation
- +6 more
-
Minneapolis, MinnesotaNovartis Investigative Site
Dec 9, 2020
Epithelial Tumors, Malignant, Malignant Solid Tumor Trial in Barcelona (NEXTGEN-TIL, Non-myeloablative Lymphodepletion (NMA-LD)
Recruiting
- Epithelial Tumors, Malignant
- Malignant Solid Tumor
- NEXTGEN-TIL
- +2 more
-
Barcelona, SpainVall d'Hebron Institute of Oncology
Nov 25, 2021
Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia Trial in Minneapolis (HSCT with TBI Regimen, HSCT with
Recruiting
- Acute Leukemia
- +27 more
- HSCT with TBI Regimen
- HSCT with Non-TBI Regimen
-
Minneapolis, MinnesotaMasonic Cancer Center at University of Minnesota
Apr 12, 2022
Leukemia, Lymphoma, Non-Hodgkin, Hematologic Diseases Trial in Stanford (Sirolimus, MMF, BCNU)
Completed
- Leukemia
- +3 more
- Sirolimus
- +6 more
-
Stanford, CaliforniaStanford University School of Medicine
Sep 16, 2021
Myeloproliferative Disorders, Leukemia, Lymphoma Trial in Minneapolis (biological, drug, procedure, radiation)
Completed
- Myeloproliferative Disorders
- +3 more
- anti-thymocyte globulin
- +6 more
-
Minneapolis, MinnesotaMasonic Cancer Center at University of Minnesota
Oct 30, 2020
Metastatic Melanoma Trial in Los Angeles (F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells, non-myeloablative
Completed
- Metastatic Melanoma
- F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells
- non-myeloablative conditioning chemotherapy
-
Los Angeles, CaliforniaUniversity of California Los Angeles, David Geffen School of Med
Dec 3, 2021
Recurrent Severe Aplastic Anemia, Refractory Severe Aplastic Anemia Trial in Duarte (biological, procedure, drug, other)
Not yet recruiting
- Recurrent Severe Aplastic Anemia
- Refractory Severe Aplastic Anemia
- Anti-Thymocyte Globulin
- +7 more
-
Duarte, CaliforniaCity of Hope Medical Center
Feb 23, 2023
Multiple Myeloma Trial in Worldwide (HLA Matched allogeneic transplant)
Completed
- Multiple Myeloma
- HLA Matched allogeneic transplant
-
Wien, Austria
- +23 more
Oct 5, 2021
Stiff-Person Syndrome Trial in Chicago (Autologous Hematopoietic Stem Cells, Cyclophosphamide, Mesna)
Terminated
- Stiff-Person Syndrome
- Autologous Hematopoietic Stem Cells
- +6 more
-
Chicago, IllinoisNorthwestern University
Jan 6, 2021
Hematologic Malignancies Trial in Lebanon (Stem Cell Transplant, G-CSF, Fludarabine)
Completed
- Hematologic Malignancies
- Stem Cell Transplant
- +5 more
-
Lebanon, New HampshireDartmouth-Hitchcock Medical Center
Oct 30, 2020
AML, MDS Trial in Belgium, United States (NKR-2)
Completed
- AML
- MDS
- NKR-2
-
Aurora, Colorado
- +6 more
Apr 30, 2021
HEMATOLOGIC MALIGNANCIES Trial in Torino (TOTAL LYMPHOID IRRADIATION)
Active, not recruiting
- HEMATOLOGIC MALIGNANCIES
- TOTAL LYMPHOID IRRADIATION
-
Torino, ItalyA.O.U. San Giovanni Battista
Feb 2, 2021
B-Cell Non-Hodgkin Lymphoma, DLBCL, Mantle Cell Lymphoma Trial in Duarte (Anti-CD19-CAR CMV-specific T-lymphocytes, Autologous
Not yet recruiting
- B-Cell Non-Hodgkin Lymphoma
- +7 more
- Anti-CD19-CAR CMV-specific T-lymphocytes
- +3 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jun 28, 2022
Multiple Myeloma Trial in United States (procedure, drug, behavioral)
Completed
- Multiple Myeloma
- One Autologous Transplant
- +5 more
-
Birmingham, Alabama
- +35 more
Oct 19, 2021
B-cell Lymphoma, Burkitt Lymphoma, Diffuse Large B Cell Lymphoma Trial in Valhalla (Polatuzumab vedotin)
Recruiting
- B-cell Lymphoma
- +8 more
- Polatuzumab vedotin
-
Valhalla, New YorkNew York Medical Center
Oct 29, 2021
Lymphoma, Non-Hodgkin Trial in United States (Hematopoietic Stem Cell Transplant)
Completed
- Lymphoma, Non-Hodgkin
- Hematopoietic Stem Cell Transplant
-
Duarte, California
- +20 more
Dec 7, 2021
Myeloid Leukemia, Chronic, Acute Myelogenous Leukemia, MDS (MDS) Trial in Palo Alto (Conventional T cells (Tcon) and Regulatory
Recruiting
- Myeloid Leukemia, Chronic
- +8 more
- Conventional T cells (Tcon) and Regulatory T cells (Treg)
-
Palo Alto, CaliforniaStanford University School of Medicine Palo Alto, California, Un
Aug 18, 2021
Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in United States (Preparative Regimen, NK Cells, Interleukin-2)
Completed
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
- Preparative Regimen
- +4 more
-
Atlanta, Georgia
- +3 more
Apr 29, 2020
Leukemia, Lymphoma, MDS Trial (biological, drug, procedure)
Withdrawn
- Leukemia
- +2 more
- filgrastim
- +4 more
- (no location specified)
Jul 29, 2020
Relapse/Refractory Multiple Myeloma Trial in Belgium, United States (CYAD-211, Endoxan, Fludara)
Recruiting
- Relapse/Refractory Multiple Myeloma
- CYAD-211
- +2 more
-
Tampa, Florida
- +4 more
Nov 26, 2020
Chronic Inflammatory Demyelinating Polyneuropathy Trial in Chicago (hematopoietic stem cell transplantation)
Completed
- Chronic Inflammatory Demyelinating Polyneuropathy
- hematopoietic stem cell transplantation
-
Chicago, IllinoisNorthwestern University, Feinberg School of Medicine
Jul 15, 2020
Acute Biphenotypic Leukemia, Acute Erythroid Leukemia in Remission, Acute Leukemia in Remission Trial in Seattle (drug,
Terminated
- Acute Biphenotypic Leukemia
- +29 more
- Cyclophosphamide
- +7 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 4, 2023
Scleroderma, Systemic Trial in Chicago (Peripheral Blood Stem Cells, Cyclophosphamide, Mesna)
Terminated
- Scleroderma, Systemic
- Peripheral Blood Stem Cells
- +6 more
-
Chicago, IllinoisNorthwestern University
Jul 7, 2020
Lymphoma, Non-Hodgkin's, Adult, Lymphoma, Hodgkin's, Adult Trial (FE 203799)
Withdrawn
- Lymphoma, Non-Hodgkin's, Adult
- Lymphoma, Hodgkin's, Adult
- FE 203799
- (no location specified)
Oct 22, 2020